On September 3, 2026 Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, reported that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During his presentations and investor meetings, Mr. Mazur will provide an overview of the Company’s business and recent developments, including the ongoing commercialization of LYMPHIR (denileukin diftitox-cxdl) by the Company’s majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), and the continued advancement of the Company’s late-stage pipeline.
Moody Capital Solutions Conference:
Conference: Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Dates: September 9–10, 2026
Location: The Westin New York Grand Central, New York, NY
Presentation Date & Time: Wednesday, September 9, 2026, 3:15 pm – 4:00 pm ET
Webcast: webcast link
H.C. Wainwright Conference:
Conference: H.C. Wainwright 28th Annual Global Investment Conference
Dates: September 14–16, 2026
Location: Lotte New York Palace Hotel, New York, NY
Presentation Date & Time: Tuesday, September 15, 2026, 2:00 pm – 2:30 pm ET
Webcast: webcast link
Please note that the presentation dates and times are subject to change. Participants should refer to the final program agenda for up-to-date information.
Investors interested in scheduling a one-on-one meeting with management should contact their conference representative or the Company’s investor relations team.
(Press release, Citius Pharmaceuticals, SEP 3, 2026, View Source [SID1234670584])